Myeloproliferative disorder therapy: Assessment and management of adverse events - A dermatologist's perspective

Hematological Oncology

Volumn 27, Issue SUPPL. 1, 2009, Pages 11-13

  Soutou, Boutros ^a   Aractingi, Sélim ^a  

^a HÔPITAL TENON   (France)

Author keywords

Adverse events; Anagrelide; Cutaneous; Essential thrombocythaemia; Hydroxyurea; Myeloproliferative disorders; Skin carcinoma

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA;

ACTINIC KERATOSIS; ALOPECIA; ARTICLE; BLOOD DISEASE; DERMATOMYOSITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EARLY DIAGNOSIS; EARLY INTERVENTION; ECZEMA; GRANULOMATOUS INFLAMMATION; HAIR LOSS; HUMAN; HYPERPIGMENTATION; ICHTHYOSIS; LEG ULCER; LICHENOID ERUPTION; MOUTH ULCER; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PATIENT REFERRAL; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; SICKLE CELL ANEMIA; SKIN BIOPSY; SKIN DISEASE; SKIN MANIFESTATION; SKIN TUMOR; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; DERMATOLOGY; DISEASE MANAGEMENT; HUMANS; MYELOPROLIFERATIVE DISORDERS; RISK ASSESSMENT; SKIN DISEASES;

EID: 67549124917     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.870     Document Type: Article

References (28)

1. Itin PH, Winkelmann RK. Cutaneous manifestations in patients with essential thrombocythemia. J Am Acad Dermatol 1991; 24: 59-63.
2. Provan D, Singer CRJ, Baglin T, Lilleyman J. Oxford Handbook of Clinical Haematology (2nd edn). Oxford University Press: Oxford, 2004.
3. Michiels JJ, ten Kate FJ. Erythromelalgia in thrombocythemia of various myeloproliferative disorders. Am J Hematol 1992; 39: 131-136.
4. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23: 441-454.
5. Michiels JJ, Abels J, Steketee J, van Vliet H, Vuzevski V. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471.
6. Bachmeyer C, Wetterwald E, Aractingi S. Cutaneous vasculitis in the course of hematologic malignancies. Dermatology 2005; 210: 8-14.
7. Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy: experience with 13 patients and literature review. Medicine 1988; 67: 220-230.
8. Stahl RL, Silber R. Vasculitic leg ulcers in chronic myelogenous leukemia. Am J Med 1985; 78: 869-872.
9. Cox NH, White SI,Walton S,Wyatt EH, Morley WN. Pyoderma gangrenosum associated with polycythemia rubra vera. Clin Exp Dermatol 1987; 12: 375-377.
10. Ho KK, Otridge BW, Vandenberg E, Powell FC. Pyoderma gangrenosum, polycythemia rubra vera, and the development of leukemia. J Am Acad Dermatol 1992; 27: 804-808.
11. Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders. Atypical forms of pyoderma gangrenosum and Sweet's syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 1983; 9: 751-758.
12. Best J, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29-32.
13. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135: 818-820.
14. Najean Y, Rain JD. Treatment of polycythemia vera: the use of Hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 9: 3370-3377.
15. Dumont-Wallon G, Milpied-Homsi B, Morineau N, Harousseau JL, Stalder JF. Cutaneomucous side effects of hydroxyurea: prospective study on 27 patients. Hématologie 2006; 12: 262-266.
16. Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001; 137: 467-470.
17. Medac GmbH. Hydroxycarbamide medac 500 mg capsule, hard. Summary of Product Characteristics, March 2005.
18. Bader U, Banyai M, Böni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? Dermatology 2000; 200: 45-48.
19. Ruzzon E, Randi ML, Tezza F, Luzzatto G, Scandellari R, Fabris F. Leg ulcers in elderly on hydroxyurea in Ph-myeloproliferative disorders and review of literature. Aging Clin Exp Res 2006; 18: 187-190.
20. Estève E, Georgescu V, Heitzmann P, Martin L. Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea. Ann Dermatol Venereol 2001; 128: 919-921.
21. Rappaport L, Körber A, Grabbe S, Dissemond J. Appearance of leg ulcers associated with intake of anagrelide. Dtsch Med Wochenschr 2007; 132: 319-321.
22. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Ruiz-Reyes G, Chernoff SG. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia. Mayo Clin Proc 1998; 73: 1125.
23. Roche Products Ltd. Roferon-A pre-filled syringe. Summary of Product Characteristics, April 2007.
24. Schering-Plough Ltd. IntronA solution for injection or infusion. Summary of Product Characteristics, April 2008.
25. Scheler M, Proelss J, Bräuninger W, Bieber T, Wenzel J. Generalized lichen nitidus with involvement of the palms following interferon alpha treatment. Dermatology 2007; 215(3): 236-2239.
26. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol 2002; 147(6): 1142-1146.
27. Vital Durand D, Durieu I, Rousset H. Toxic or drug-induced granulomatous reactions. Rev Med Interne 2008; 29(1): 33-38.
28. Schapira D, Nahir AM, Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 2002; 32(3): 157-162.